



## Impact of Immunization Safety Monitoring on Vaccine Coverage

Guest Editor:

**Dr. Jane F. Gidudu**

Global Immunization Division,  
Centers for Disease Control and  
Prevention, Atlanta, GA, USA

Deadline for manuscript  
submissions:

**30 November 2024**

### Message from the Guest Editor

Dear Colleagues,

Despite progress in immunization recovery, immunization coverage remains lower than before the COVID-19 pandemic. Global immunization stakeholders have committed to achieving immunization recovery and reaching zero-dose communities. They are focusing their efforts on raising vaccination levels and protecting vulnerable and special populations from vaccine-preventable diseases. In addition to ensuring equitable access to immunizations, it is essential to consider immunization safety concerns, as they are a significant driver of vaccine hesitancy.

This Special Issue aims to highlight immunization safety in improving immunization coverage. We welcome original research articles and reviews focusing on research areas that include disparities in immunization coverage, immunization safety, active vaccine safety surveillance, adverse events following immunization, digital innovations for immunization program monitoring, barriers to reporting immunization safety events, advances to address immunization safety information and strategies to increase the demand for vaccines.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)